Mcdaniel Terry & Co. Sells 713 Shares of Becton, Dickinson and Company $BDX

Mcdaniel Terry & Co. cut its stake in Becton, Dickinson and Company (NYSE:BDX) by 0.8% in the second quarter, HoldingsChannel reports. The fund owned 87,198 shares of the medical instruments supplier’s stock after selling 713 shares during the period. Becton, Dickinson and Company accounts for 1.2% of Mcdaniel Terry & Co.’s holdings, making the stock its 29th largest position. Mcdaniel Terry & Co.’s holdings in Becton, Dickinson and Company were worth $15,020,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds have also modified their holdings of the company. Saudi Central Bank bought a new position in Becton, Dickinson and Company in the 1st quarter worth approximately $26,000. Smallwood Wealth Investment Management LLC bought a new stake in shares of Becton, Dickinson and Company during the first quarter worth $27,000. Alpine Bank Wealth Management acquired a new position in shares of Becton, Dickinson and Company during the first quarter valued at $29,000. Cornerstone Planning Group LLC boosted its holdings in Becton, Dickinson and Company by 341.4% in the first quarter. Cornerstone Planning Group LLC now owns 128 shares of the medical instruments supplier’s stock valued at $29,000 after acquiring an additional 99 shares during the last quarter. Finally, Kelly Lawrence W & Associates Inc. CA bought a new stake in Becton, Dickinson and Company during the 1st quarter worth about $31,000. 86.97% of the stock is owned by institutional investors.

Analyst Ratings Changes

BDX has been the subject of a number of recent research reports. Wall Street Zen raised shares of Becton, Dickinson and Company from a “hold” rating to a “buy” rating in a research note on Saturday, August 9th. Argus increased their price target on Becton, Dickinson and Company from $220.00 to $230.00 in a research note on Monday, September 15th. Royal Bank Of Canada restated a “sector perform” rating and issued a $211.00 price target on shares of Becton, Dickinson and Company in a research report on Thursday, October 16th. Wells Fargo & Company upped their price objective on Becton, Dickinson and Company from $172.00 to $184.00 and gave the company an “equal weight” rating in a report on Friday, August 8th. Finally, Piper Sandler reaffirmed a “neutral” rating and issued a $200.00 price target (up from $185.00) on shares of Becton, Dickinson and Company in a research note on Friday, August 8th. Three analysts have rated the stock with a Buy rating and nine have given a Hold rating to the company. According to MarketBeat.com, the company has an average rating of “Hold” and an average price target of $205.40.

Becton, Dickinson and Company Stock Down 0.4%

NYSE:BDX opened at $185.85 on Friday. Becton, Dickinson and Company has a 1 year low of $163.33 and a 1 year high of $251.99. The stock has a 50-day moving average price of $189.93 and a two-hundred day moving average price of $184.08. The stock has a market cap of $53.27 billion, a price-to-earnings ratio of 33.43, a PEG ratio of 1.46 and a beta of 0.25. The company has a current ratio of 1.10, a quick ratio of 0.62 and a debt-to-equity ratio of 0.69.

Becton, Dickinson and Company (NYSE:BDX) last issued its quarterly earnings data on Thursday, April 14th. The medical instruments supplier reported $4.10 earnings per share (EPS) for the quarter. Becton, Dickinson and Company had a return on equity of 16.23% and a net margin of 7.51%.The business had revenue of $5.32 billion during the quarter. As a group, equities analysts expect that Becton, Dickinson and Company will post 14.43 earnings per share for the current year.

Insider Activity

In other news, Director Claire Fraser sold 917 shares of the stock in a transaction on Wednesday, September 10th. The shares were sold at an average price of $187.50, for a total transaction of $171,937.50. Following the completion of the sale, the director owned 22,226 shares of the company’s stock, valued at $4,167,375. This represents a 3.96% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Insiders have sold a total of 1,838 shares of company stock worth $348,392 over the last ninety days. 0.36% of the stock is owned by corporate insiders.

About Becton, Dickinson and Company

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.